Peptron

087010.KQ

182.61 USD

7.71

+4.41%

Overview

Last close

182.61 usd

Market cap

2.80B usd

52 week high

262.86 usd

52 week low

31.71 usd

Target price

24.02 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

977.9648

Price/Book Value

42.2532

Enterprise Value

4.19B usd

EV/Revenue

986.1279

EV/EBITDA

-17.5233

Key financials

Revenue TTM

3.99M usd

Gross Profit TTM

3.07M usd

EBITDA TTM

-7.37M usd

Earnings per Share

N/A usd

Dividend

N/A usd

Total assets

131.18M usd

Net debt

20.37M usd

About

Peptron, Inc. engages in the development of peptide-based medicines. The company's technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. Its research and development products include Luphere Depot for prostate cancer, endometriosis, uterine fibroids, premenopausal breast cancer, and puberty; SR-Octreotide for the treatment of acromegaly; SR-Exenatide to treat type 2 diabetes; and SR-Exenatide (PT320) for Parkinson's and Alzheimer's disease. Peptron, Inc. was founded in 1997 and is headquartered in Daejeon, South Korea.